KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Consolidated Net Income: 2009-2025

Historic Consolidated Net Income for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $432.0 million.

  • Teva Pharmaceutical Industries' Consolidated Net Income rose 209.92% to $432.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $658.0 million, marking a year-over-year increase of 125.84%. This contributed to the annual value of -$2.0 billion for FY2024, which is 217.67% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Consolidated Net Income of $432.0 million as of Q3 2025, which was up 53.74% from $281.0 million recorded in Q2 2025.
  • Teva Pharmaceutical Industries' Consolidated Net Income's 5-year high stood at $519.0 million during Q1 2024, with a 5-year trough of -$1.8 billion in Q4 2023.
  • Moreover, its 3-year median value for Consolidated Net Income was -$253.0 million (2023), whereas its average is -$270.2 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first plummeted by 1,286.59% in 2022, then spiked by 305.14% in 2024.
  • Over the past 5 years, Teva Pharmaceutical Industries' Consolidated Net Income (Quarterly) stood at -$151.0 million in 2021, then slumped by 783.44% to -$1.3 billion in 2022, then plummeted by 34.63% to -$1.8 billion in 2023, then soared by 84.69% to -$275.0 million in 2024, then soared by 209.92% to $432.0 million in 2025.
  • Its Consolidated Net Income was $432.0 million in Q3 2025, compared to $281.0 million in Q2 2025 and $220.0 million in Q1 2025.